Loading
Vaccines and Immunoinformatics Approaches · Journal article
The Journal of Immunology · July 28, 2026
Raises a question worth testing. It does not answer one.
This study uses TCR sequencing and antigen discovery in Mtb-exposed IGRA-negative and IGRA-positive individuals to identify Rv2140c as a novel Mtb antigen and propose follicular helper T cells as a protective mechanism distinct from classic Th1 responses. The work is exploratory and mechanistic, lacks clinical outcome validation, and does not report sample sizes or statistical comparisons.
Cross-sectional comparative study using TCR sequencing, epitope discovery, and single-cell multi-omics. Mtb-exposed IGRA-negative individuals ("resisters") and IGRA-positive individuals from Uganda and South Africa. Intervention: TCR sequencing, antigen discovery, and immunological characterization of Mtb-specific CD4+ T cells. Compared with: IGRA-negative resisters versus IGRA-positive individuals. Uganda and South Africa.
24 TCR specificity groups uniquely enriched in IGRA-negative resisters identified by GLIPH3 algorithm Two ligand peptides decoded from Mtb antigens Rv2140c and ESAT6 Rv2140c-specific CD4 T cells predominantly follicular helper cells (Tfh) in IGRA-negative individuals; IGRA-positive individuals showed primarily Th1 responses
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This hypothesis-generating work suggests Rv2140c as a potential vaccine candidate and identifies Tfh cells as a possible protective mechanism in Mtb control. However, the absence of clinical outcome data and sample size reporting precludes recommendation for clinical application or vaccine development decisions at this stage.
This is an exploratory mechanistic study using novel discovery platforms in small populations that identifies a candidate antigen and proposes a new protective mechanism, but lacks clinical validation or outcome data to confirm the hypothesis.
As stated by the source record.
This hypothesis-generating work suggests Rv2140c as a potential vaccine candidate and identifies Tfh cells as a possible protective mechanism in Mtb control. However, the absence of clinical outcome data and sample size reporting precludes recommendation for clinical application or vaccine development decisions at this stage.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Abstract Introduction Mycobacterium tuberculosis (Mtb) remains a leading cause of death worldwide. IFNγ Release Assay (IGRA) is widely used to diagnose Mtb infection by measuring the IFNγ response to Mtb antigens. However, healthy IGRA- individuals with high Mtb exposure (“resisters”) have shown evidence of infection and make Mtb-specific responses that differ from IGRA+ individuals. Human CD4 T cells are critical in controlling Mtb. IFNγ-expressing Th1 cells are largely believed to be the major protective subset. Resisters’ negative response to IGRA suggests alternative protective mechanisms of CD4 T cells. This study aims to profile the antigen-specific CD4+ T cell responses in Mtb-exposed IGRA- individuals. Methods We performed TCR sequencing on Ugandan resisters and IGRA+ individuals. TCR repertoires were analyzed with GLIPH3 algorithm we recently developed to identify resister-specific TCRs. Mtb antigenic ligands were discovered by a new T cell epitope discovery platform. Antigen-specific CD4+ T cells were then isolated using peptide-MHC multimers covering the discovered antigenic peptide, and characterized by single-cell multi-omics and Flow Cytometry. Results We identified 24 TCR specificity groups uniquely enriched in resisters. Two ligand peptides were decoded from Mtb antigens Rv2140c and ESAT6. In a parallel South African cohort, in IGRA- individuals, we detected T cell responses to ESAT6, the antigen used in IGRA test, and a robust response to Rv2140c. Notably, Rv2140c-specific CD4 T cells were predominantly follicular helper cells (Tfh), which correlated with protection from Mtb in mice, whereas IGRA+ individuals showed primarily Th1 responses. Conclusion We identified a novel Mtb antigen associated with protection, highlighting its potential as vaccine candidate. ESAT6-specific responses in IGRA- individuals confirmed underlying Mtb infection, indicating the limitations of IGRA tests. The predominance of Tfh cells reveals new protective human T cell mechanism against Mtb beyond the classic Th1 response. Funding Source Bill & Melinda Gates Foundation Topic Categories Microbial, Parasitic, and Fungal Immunology (MPF)
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.